论文部分内容阅读
随着慢性肾功能衰竭患者生存时间的延长,慢性肾脏病-矿物质和骨代谢紊乱(CKD-MBD)的发病率随之呈明显上升趋势,严重影响着透析患者的生活质量及生命安全。而对其病因病机的深入研究可为临床提供明确诊断并进行有效的针对性治疗。其发病机制包括代谢紊乱、成纤维细胞生长因子23、克罗索蛋白、Dickkopf1及活化素与骨形态蛋白-7等。目前西医对CKD-MBD的治疗以改善代谢紊乱与继发性甲状旁腺功能亢进为主,中医对其病因病机虽尚无统一认识,但治疗上则在辨证论治的基础上治以补肾壮骨为主。人们对CKD-MBD的深入研究将有助于指导临床诊治与预防,提高患者的生活质量。
With the prolongation of survival time in patients with chronic renal failure, the incidence of chronic kidney disease - mineral and bone metabolic disorders (CKD-MBD) is followed by a significant upward trend, seriously affecting the quality of life and life safety of dialysis patients. In-depth study of its etiology and pathogenesis can provide a clear diagnosis for clinical and effective targeted treatment. The pathogenesis of metabolic disorders, including, fibroblast growth factor 23, cross-linked protein, Dickkopf1 and activin and BMP-7 and so on. At present, Western medicine on the treatment of CKD-MBD to improve metabolic disorders and secondary hyperparathyroidism based on the etiology and pathogenesis of Chinese medicine although there is no uniform understanding, but the treatment is in the syndrome differentiation based on the treatment of kidney and Zhuanggu Mainly. People in-depth study of CKD-MBD will help guide the clinical diagnosis and treatment, improve the quality of life of patients.